【Abstract】 Objective To research effects of the levocarnitine jointed hemodialysis on the heart function, T lymphocyte subgroup, and the soluble interleukin 2 receptor (SIL2R) for the endstage kidney disease.Methods 86 patients with endstage renal disease according to lottery method were divided into control group (n=43) and research group (n=43). The control group was treated with hemodialysis. The research group was treated based on control group and with L-carnitine. Clinical curative effects, LVMI, LVEF, CO, CD3+, CD4+, CD8+, CD4+/CD8+, SIL2R before and after treatment, and security between two groups were compared.Results Total effective rate of the research group (8837%) was higher than that of the control group (6977%) (P＜005). Before treatment, LVMI, LVEF, CO, CD3+, CD4+, CD8+, CD4+/CD8+, SIL2R of the two group were of no differene (P＞005) . LVMI, LVEF, CO, CD3+, CD4+, CD4+/CD8+ of the two groups after treatment were higher than before treatment. CD8+, SIL2 R of the two group after treatment was lower than that before treatment. CD8+, SIL2 R of the research group was obviously lower than that of the control group (P＜005). The adverse reactions of the two groups were not different (P＞005).Conclusion The efficacy of the levocarnitine jointed hemodialysis in treatment endstage nephropathy is better than that of hemodialysis alone, which can effectively improve cardiac function and T lymphocyte subsets and reduce the concentration of SIL2R.